

Table 1a. Antibody Performance, Weeks 1 and 2 – IgM

IgM	Week 1			Week 2		
Sensitivity	0.33 (95% CI: 0.25 to 0.41)			0.73 (95% CI: 0.66 to 0.78)		
Specificity	0.98 (95% CI: 0.97 to 0.99)					
Outcome	Effect per 1,000 patients tested					
	pre-test probability of 1% ^a	pre-test probability of 10% ^b	pre-test probability of 40% ^c	pre-test probability of 1% ^a	pre-test probability of 10% ^b	pre-test probability of 40% ^c
True positives (patients with COVID-19)	3 (3 to 4)	33 (25 to 41)	132 (100 to 164)	7 (7 to 8)	73 (66 to 78)	292 (264 to 312)
False negatives (patients incorrectly classified as not having COVID-19)	7 (6 to 7)	67 (59 to 75)	268 (236 to 300)	3 (2 to 3)	27 (22 to 34)	108 (88 to 136)
Quality of the evidence	12 studies, 919 patients ⊕⊕○○ LOW ^{d, e}			16 studies, 2309 patients ⊕⊕○○ LOW ^{d, e}		
	pre-test probability of 1% ^a		pre-test probability of 10% ^b		pre-test probability of 40% ^c	
True negatives (patients without COVID-19)	970 (960 to 980)		882 (873 to 891)		588 (582 to 594)	
False positives (patients incorrectly classified as having COVID-19)	20 (10 to 30)		18 (9 to 27)		12 (6 to 18)	
Quality of Evidence	21 studies, 7165 patients ⊕⊕⊕○ MODERATE ^d					

a. Typically seen in general population in areas that are not hotspots

b. Typically seen in general population in high risk populations

c. Typically seen in general population in exposed and nursing homes

d. The case-control design leads to a serious risk of bias

e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C1: 0.06-0.62, C2: 0.33-1.00